DexCom (DXCM) Getting Somewhat Positive Media Coverage, Report Finds
Media coverage about DexCom (NASDAQ:DXCM) has been trending somewhat positive on Sunday, according to Accern Sentiment. Accern scores the sentiment of press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. DexCom earned a media sentiment score of 0.09 on Accern’s scale. Accern also gave media headlines about the medical device company an impact score of 45.2613649320193 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
DexCom (DXCM) traded up $1.56 on Friday, hitting $61.53. 2,116,764 shares of the company traded hands, compared to its average volume of 1,585,820. The company has a debt-to-equity ratio of 0.84, a quick ratio of 5.50 and a current ratio of 5.86. DexCom has a twelve month low of $42.62 and a twelve month high of $88.80.
DXCM has been the subject of a number of recent research reports. TheStreet downgraded shares of DexCom from a “c-” rating to a “d+” rating in a report on Wednesday, October 25th. ValuEngine upgraded shares of DexCom from a “sell” rating to a “hold” rating in a report on Friday, September 1st. Wedbush reiterated a “buy” rating and set a $76.00 price target on shares of DexCom in a report on Wednesday, October 4th. Robert W. Baird reiterated a “hold” rating and set a $79.00 price target on shares of DexCom in a report on Sunday, September 10th. Finally, Barclays initiated coverage on shares of DexCom in a report on Friday, September 15th. They set an “equal weight” rating and a $76.00 price target for the company. One analyst has rated the stock with a sell rating, nine have issued a hold rating and fourteen have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $70.69.
DexCom Company Profile
Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.
Receive News & Stock Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related stocks with our FREE daily email newsletter.